142 related articles for article (PubMed ID: 38012658)
1. The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
Wang Y; Dong S; Hu K; Xu L; Feng Q; Li B; Wang G; Chen G; Zhang B; Jia X; Xu Z; Gao X; Zhang H; Xie Y; Lu M; Chang S; Song D; Wu X; Jia Q; Zhu H; Zhou J; Zhu W; Shi J
J Transl Med; 2023 Nov; 21(1):858. PubMed ID: 38012658
[TBL] [Abstract][Full Text] [Related]
2. A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.
Wang Y; Huang J; Li B; Xue H; Tricot G; Hu L; Xu Z; Sun X; Chang S; Gao L; Tao Y; Xu H; Xie Y; Xiao W; Yu D; Kong Y; Chen G; Sun X; Lian F; Zhang N; Wu X; Mao Z; Zhan F; Zhu W; Shi J
Cancer Res; 2020 Feb; 80(3):536-548. PubMed ID: 31732653
[TBL] [Abstract][Full Text] [Related]
3. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo.
Dong S; Hu K; Shi Y; Wang G; Yu D; Zhao Y; Zhang H; Wang Y; Sun H; Xu Z; Jia Q; Li Y; Li Y; Li B; Shi J; Zhu W
Bioorg Med Chem Lett; 2024 Jan; 98():129590. PubMed ID: 38092072
[TBL] [Abstract][Full Text] [Related]
5. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
[TBL] [Abstract][Full Text] [Related]
6. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
7. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
8. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.
Li C; Xia J; Franqui-Machin R; Chen F; He Y; Ashby TC; Teng F; Xu H; Liu D; Gai D; Johnson SK; van Rhee F; Janz S; Shaughnessy JD; Tricot G; Frech I; Zhan F
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061780
[TBL] [Abstract][Full Text] [Related]
9. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone.
Chen F; Wang S; Wei Y; Wu J; Huang G; Chen J; Shi J; Xia J
Biomed Pharmacother; 2018 Jul; 103():1092-1100. PubMed ID: 29710674
[TBL] [Abstract][Full Text] [Related]
10. Norcantharidin induces apoptosis in HeLa cells through caspase, MAPK, and mitochondrial pathways.
An WW; Gong XF; Wang MW; Tashiro S; Onodera S; Ikejima T
Acta Pharmacol Sin; 2004 Nov; 25(11):1502-8. PubMed ID: 15525474
[TBL] [Abstract][Full Text] [Related]
11. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
Zhou XY; Shu XM
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
[TBL] [Abstract][Full Text] [Related]
13. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
Chang S; Xiao W; Xie Y; Xu Z; Li B; Wang G; Hu K; Zhang Y; Zhou J; Song D; Zhu H; Wu X; Lu Y; Shi J; Zhu W
Cancer Med; 2023 Dec; 12(23):21321-21334. PubMed ID: 37942576
[TBL] [Abstract][Full Text] [Related]
14. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
15. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
[TBL] [Abstract][Full Text] [Related]
16. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.
Zhang JT; Sun W; Zhang WZ; Ge CY; Liu ZY; Zhao ZM; Lu XS; Fan YZ
BMC Cancer; 2014 Mar; 14():193. PubMed ID: 24628713
[TBL] [Abstract][Full Text] [Related]
17. Contribution of p38 MAPK Pathway to Norcantharidin-Induced Programmed Cell Death in Human Oral Squamous Cell Carcinoma.
Ahn CH; Hong KO; Jin B; Lee W; Jung YC; Lee H; Shin JA; Cho SD; Hong SD
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31315217
[TBL] [Abstract][Full Text] [Related]
18. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
[TBL] [Abstract][Full Text] [Related]
19. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
Zhang G; Zhu Q; Fu G; Hou J; Hu X; Cao J; Peng W; Wang X; Chen F; Cui H
Br J Cancer; 2019 Dec; 121(12):1069-1078. PubMed ID: 31740732
[TBL] [Abstract][Full Text] [Related]
20. Norcantharidin induces G2/M arrest and apoptosis via activation of ERK and JNK, but not p38 signaling in human renal cell carcinoma ACHN cells.
Huang S; Tuergong G; Zhu H; Wang X; Weng G; Ren Y
Acta Pharm; 2021 Jun; 71(2):267-278. PubMed ID: 33151174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
